28
Participants
Start Date
September 3, 2019
Primary Completion Date
July 23, 2021
Study Completion Date
July 23, 2021
Liposomal bupivacaine
Liposomal bupivacaine is a novel formulation of local bupivacaine and allows prolonged release of the medication, thereby providing longer lasting effects. It is approved by the FDA and has been shown to provide excellent pain control after surgery.
Bupivacaine Hydrochloride
We currently administer local plain bupivacaine during vaginal hysterectomy to decrease pain in the postoperative period. Bupivacaine is an anesthetic that works by blocking nerve conduction and producing a numbing effect.
Mayo Clinic in Arizona, Phoenix
Lead Sponsor
Collaborators (1)
Pacira Pharmaceuticals, Inc
INDUSTRY
Mayo Clinic
OTHER